Clinical trials: Metastatic Clear-cell Renal Cancer
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
- Conditions
- Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms
- Trial name
- NCT02837991
- Testing
- CDX-014
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celldex Therapeutics
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT01835158
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
- Where
- 488 sites in United States
- Volunteers
- 157 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
RATIONALE: Panobinostat and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01582009
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
This phase II trial investigates the effect of sitravatinib and nivolumab in treating patients with clear cell renal cell cancer that has spread to other places in the body (metastatic/advanced).
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT04904302
- Testing
- Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cancer
Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney.
- Trial name
- SPECTRE (NCT06863857)
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hereditary Clear Cell Renal Cell Carcinoma, Kidney Cancer
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00727532
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Kidney Cancer, Metastatic Cancer
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00588913
- Testing
- aldesleukin, therapeutic autologous lymphocytes, zoledronic acid
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Tokyo Women's Medical University
Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
This is a multicenter, single-arm, phase 2 clinical trial designed to evaluate the clinical efficacy of combination therapy with zanzalintinib and pembrolizumab in patients with locally advanced intermediate- to high-risk…
- Trial name
- NCT07691476
- Testing
- Zanzalintinib and Pembrolizumab
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Metastatic Clear Cell Renal Cell Carcinoma
68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma
This is a prospective, single-center, single-arm, comparative phase 2 study in patients with metastatic clear cell renal cell carcinoma.
- Trial name
- NCT05879471
- Testing
- 68Ga-NY104 PET/CT
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Renal Cell Carcinoma
Functional Imaging in the Assessment of mRCC Response to Sunitinib
The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic…
- Trial name
- NCT01977586
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United Kingdom
- Sponsor
- Imperial College Healthcare NHS Trust
Clear Cell Metastatic Renal Cell Carcinoma
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
Stereotactic radiotherapy (SRT) is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs.
- Trial name
- NCT02019576
- Testing
- Stereotactic radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 38 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Renal Cell Carcinoma, Kidney Neoplasm
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible.
- Conditions
- Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
- Trial name
- INDIGO (NCT04644432)
- Testing
- Medication (A specification is listed under each arm), Patient reported outcomes measurement
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Herlev and Gentofte Hospital
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care.
- Conditions
- Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Trial name
- EXACT (NCT06863311)
- Testing
- XL092, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Karie Runcie
Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.
- Conditions
- Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Melanoma
- Trial name
- NCT03679767
- Testing
- Retifanlimab
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 121 people
- Sponsor
- Incyte Corporation
Carcinoma, Renal Cell
Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
The purpose of this study was to evaluate the safety and efficacy of CAP-232 in the treatment of patients with previously treated (refractory) renal cell carcinoma
- Trial name
- NCT00422786
- Testing
- CAP-232
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Thallion Pharmaceuticals